ALK-Abelló A/S (ALK-B.CO)

DKK 161.5

(5.56%)

EBITDA Summary of ALK-Abelló A/S

  • ALK-Abelló A/S's latest annual EBITDA in 2023 was 913 Million DKK , up 28.91% from previous year.
  • ALK-Abelló A/S's latest quarterly EBITDA in 2024 Q2 was 329 Million DKK , down -13.35% from previous quarter.
  • ALK-Abelló A/S reported an annual EBITDA of 705 Million DKK in 2022, up 30.33% from previous year.
  • ALK-Abelló A/S reported an annual EBITDA of 524 Million DKK in 2021, up 42.78% from previous year.
  • ALK-Abelló A/S reported a quarterly EBITDA of 329 Million DKK for 2024 Q2, down -13.35% from previous quarter.
  • ALK-Abelló A/S reported a quarterly EBITDA of 157 Million DKK for 2023 Q2, down -45.49% from previous quarter.

Annual EBITDA Chart of ALK-Abelló A/S (2023 - 2002)

Historical Annual EBITDA of ALK-Abelló A/S (2023 - 2002)

Year EBITDA EBITDA Growth
2023 913 Million DKK 28.91%
2022 705 Million DKK 30.33%
2021 524 Million DKK 42.78%
2020 311 Million DKK 53.63%
2019 228 Million DKK 55.0%
2018 115 Million DKK -31.62%
2017 75 Million DKK -67.81%
2016 655 Million DKK 26.66%
2015 572 Million DKK 17.14%
2014 455 Million DKK 100.82%
2013 242 Million DKK -21.79%
2012 248 Million DKK -28.44%
2011 436 Million DKK 41.56%
2010 308 Million DKK 11.19%
2009 277 Million DKK 13.06%
2008 245 Million DKK -22.47%
2007 316 Million DKK 89.22%
2006 168 Million DKK 135.21%
2005 71 Million DKK 0.0%
2004 - DKK 0.0%
2003 - DKK 0.0%
2002 - DKK 0.0%

Peer EBITDA Comparison of ALK-Abelló A/S

Name EBITDA EBITDA Difference
Bavarian Nordic A/S 2.05 Billion DKK 55.502%
Genmab A/S 5.56 Billion DKK 83.582%
Gubra A/S -28.89 Million DKK 3259.716%
Novo Nordisk A/S 113.33 Billion DKK 99.194%
Orphazyme A/S -26.04 Million DKK 3605.068%
Pharma Equity Group A/S -24.79 Million DKK 3781.6%
Zealand Pharma A/S -651.58 Million DKK 240.121%